

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:

"Assistant Commissioner for Patents  
Washington, D.C. 20231"

December 15, 2003

ELLEN PLOTKIN  
Reg. No. 36,636  
Attorney for Applicant(s)

12/15/03  
Date of  
Signature

**PATENT**  
#02-0544-UNI  
Case #T3089(C)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Cobain et al.  
Serial No.: 10/660,125  
Filed: September 11, 2003  
For: PSYCHOLOGICAL STRESS IN HUMANS

Edgewater, New Jersey 07020  
December 15, 2003

**SUBMISSION OF PRIORITY DOCUMENT**


Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to rule 55(b) of the Rules of Practice in Patent Cases, Applicant(s) is/are submitting herewith a certified copy of the United Kingdom Application No. 0221306.4 filed September 13, 2002, upon which the claim for priority under 35 U.S.C. § 119 was made in the United States.

It is respectfully requested that the priority document be made part of the file history.

Respectfully submitted,

  
Ellen Plotkin  
Reg. No. 36,636  
Attorney for Applicant(s)

EP/mt  
(201) 840-2253





INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 19 August 2003




## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH



1. Your reference

RMW/T3089(C)

14SEP02 E748209-2 C03008

1/7700 0.00-0221306.4

2. Patent application number

0221306.4

(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

UNILEVER PLC  
Unilever House  
Blackfriars  
LONDON  
EC4P 4BQ  
GB

13 SEP 2002

Patents ADP number (*if you know it*)

1628002

If the applicant is a corporate body, give the country/state of its incorporation

GB

4. Title of the invention

PSYCHOLOGICAL STRESS IN HUMANS

5. Name of your agent (*if you have one*)

LLOYD WISE

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

Commonwealth House  
1-19 New Oxford Street  
London WC1A 1LW  
England

Patents ADP number (*if you know it*)

117001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications (*and if you know it*) the or each application number

Country

Priority application  
number  
(*if you know it*)

Date of filing  
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request (*Answer 'Yes' if:*

YES

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description 19

Claim(s) 1

Abstract 1

Drawing(s) 5

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translation of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date 13 September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

ROBIN MICHAEL WALDREN  
020 7571 6200

**Warning**

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay, please contact the Patent Office.

## Psychological Stress In Humans

5

### Field of the invention

10 The present invention relates to the field of psychological stress in humans, more particularly the invention relates to the diagnosis of human psychological stress.

### Background to the invention

15 Psychological stress, also known as psycho-neuro-endocrine stress, involves an assessment of the biological mechanisms underlying this psychological state. The current approach is to focus on the output of the Hypothalamic-Pituitary-Adrenal (HPA) axis, since stressful events activate this system. The hypothalamus secretes corticotrophin releasing hormone (CRH) in response to stimulation. CRH then stimulates the pituitary gland to secrete adrenocorticotrophin releasing hormone (ACTH) which in  
20 turn stimulates the adrenal cortex to secrete cortisol. Increased stimulation of the HPA axis via perceived stressful events therefore results in an increased production of cortisol. The sympathetic nervous system is also activated by stress and increased activity, as measured by the output of adrenaline and noradrenaline can also be considered a marker of psychological stress.

25

Cortisol can be easily measured in saliva and has conventionally been used as a marker of psychological stress. Numerous cross-sectional and longitudinal studies have demonstrated the utility of measuring cortisol as a marker of stress (Seeman et al.2001, Lupien et al.1997).

30

The "Allostatic Load" principle that has been developed by McEwen and Seeman (Seeman et al., 1997) suggests that repeated physiological stress puts our body at risk of long term damage. They have demonstrated this by showing that individuals with high levels of cortisol are more likely to demonstrate functional declines in physical and  
35 cognitive function.

Although an individual may be reasonably reliable at detecting their own acute stress e.g. feeling "stressed" when giving a public presentation, detection by an individual of the cumulative damage that results from repeated activation of the HPA axis over a longer period is much more difficult. It would be clearly desirable to offer a reliable means of monitoring an individual's allostatic load to increase their awareness of exposure to long term psychological stress and to thereby allow preventative steps to be taken to reduce the associated health risks.

While cortisol has been shown to be an effective marker of stress, rapid cortisol release into body fluids in response to perceived stressful events can cause large fluctuations in circulating cortisol during a daily period. Such fluctuations mask underlying and long term trends and render cortisol a poor marker of allostatic load in a single sample assessment and therefore unsuitable for identifying the individual suffering exposure to long term psychological stress.

Isoprostanes are prostaglandin like compounds which are formed *in vivo* by predominantly free radical catalysed non-enzymatic peroxidation of arachidonic acid. Circulating and urinary levels of F2-isoprostanes are known to be high in patients with pathologies involving oxidant stress and also in models with oxidative damage. US 5,891,622 discloses a process for determination of oxidative stress through a comparison wherein the amount of isoprostane increase in a sample isolated from an organism undergoing oxidative stress is compared to a control. The prior art contains no hint or suggestion of any link between the two wholly distinct conditions of oxidative and psychological stress.

The objective technical problem addressed by the present invention is therefore to provide a process by which the damage to a human body accrued as a result of long term psychological stress can be assessed.

The solution to this problem is based on the finding that isoprostane molecules present in human biological fluids offer a reliable marker of long term psychological stress. In particular, the presence of psychological stress or increased psychological stress levels can be identified by an increase in the level of one or more isoprostanes.



### Definitions

For the purpose of the present invention an "isoprostane" refers to a free radical catalysed nonenzymic peroxidation product of arachidonic acid. These molecules are preferably selected from the group comprising F<sub>2</sub>-isoprostanes, isoprostanes containing D/E-prostane rings (D<sub>2</sub>-isoprostanes, E<sub>2</sub>-isoprostanes) and isoprostanes comprising cyclopentenone ring structures (A<sub>2</sub>-isoprostanes, J<sub>2</sub>-isoprostanes and thromboxane-like isoprostanes, termed isothromboxanes (Liu et al. 1999).

The expression "F<sub>2</sub>-isoprostane" is used herein to refer to a specific group of isoprostanes which are formed when arachidonic acid undergoes hydrogen and oxygen insertion, wherein depending on the site, four different peroxy radical isomers are formed. Endocyclization of the radical occurs, followed by the addition of another oxygen molecule to yield endoperoxide (PGG<sub>2</sub>-like) regioisomers. These intermediates are then reduced to F<sub>2</sub>-IsoPs. Four regioisomers are formed and are designated as either 5-series, 12-series, 8-series or 15-series compounds depending on the carbon to which the side chain hydroxyl is attached. Each of the four regioisomers can have eight racemic diastereomers thus F<sub>2</sub>-IsoPs for the purpose of the invention may comprise one or more of the sixty-four different compounds generated by this process (Morrow et al., 1997).

A biological marker is defined as a molecular indicator present in a sample of biological origin, wherein said indicator allows the diagnosis of a particular clinical condition to be made.

### Definition of the Invention

Thus, a first aspect of the present invention provides use of one or more isoprostanes as a biological marker of psychological stress in humans.

A second aspect of the present invention provides use of a means for measuring one or more isoprostanes in determining psychological stress levels in humans.

A third aspect of the present invention provides a method of determining psychological stress level in a human by measuring the level of one or more isoprostanes in a biological sample derived from the human.

5    Brief description of the invention

Having hereby identified a significant positive correlation between isoprostanes and their metabolites in human body fluids and psychological stress, it is a first object of the invention to provide the use of one or more isoprostanes as a biological marker of  
10   psychological stress in humans.

A plurality of means by which isoprostane levels may be measured have been described in the art for purposes differing to that of the present invention. A second object of the invention therefore provides the use of a means for measuring one or more isoprostanes,  
15   and/or their metabolites in determining psychological stress levels in humans.

Isoprostanes may be measured in a plurality of human body fluids, in a preferred embodiment the invention comprises the use as described above wherein isoprostanes and/or their metabolites are measured in one or more fluids selected from the group  
20   comprising urine, blood, tears, sweat and saliva.


Urine has been found to offer a particularly suitable body fluid in which isoprostanes or their urinary metabolite forms of isoprostanes may be monitored. Urine that has been accumulating in the bladder for a period of more than 5 hours, more preferably for a  
25   period more than 8 hours provides a more reliable sample source. In a most preferred embodiment urine taken from overnight bladder accumulation has been found to provide most accurate results by minimising the potential influence of diet and physical activity on basal isoprostane levels.

30   Antibodies or antibody fragments are effective at detecting isoprostanes and therefore in a second embodiment the invention comprises a use as described above wherein said means for measuring said one or more isoprostanes comprises one or more antibodies and/or antibody fragments directed thereto.

35   Psychological stress is also recognised as interrelated with further psychological conditions selected from the group comprising depression, generalised anxiety disorder,


post traumatic stress disorder, panic, chronic fatigue and ME. Hence, a further embodiment of the invention relates to a use according as described above, wherein said psychological stress is associated with one or more conditions selected from the group comprising clinical depression, post traumatic stress disorder, chronic fatigue syndrome and ME.

In seeking to monitor psychological stress through analysis of a urine sample it has been found that the  $F_2$ -isoprostanes are a particularly effective marker. Therefore a preferred embodiment comprises the use as described above wherein one or more  $F_2$ -isoprostanes is a 8- $F_2$ -IsoP, as in I, and/or a racemic diastereoisomer thereof.



8-iso. PGF<sub>2</sub>α

It has also been found that the isoprostane metabolite, 2,3-dinor-8-iso Prostaglandin  $F_{1\alpha}$  is particularly effective as a biological marker of psychological stress. Therefore a further embodiment of the invention comprises the use as described above wherein said isoprostane metabolite is a 2,3-dinor-8-iso Prostaglandin  $F_{1\alpha}$  according to the formula II (and/or a racemic diastereoisomer thereof).

2,3-dinor-8-iso Prostaglandin F<sub>1α</sub>

(II)

5 In order to help separate the effect of psychological stress on isoprostanes from other factors which may also affect or increase isoprostane levels, measurement of one or more secondary psychological stress related markers may also be determined, for example, selected from raised blood pressure, raised heart rate, increased sweating, increased tremor, levels of cortisol, adrenaline, noradrenalin and use of a questionnaire indicative of stress levels.

10 The present invention therefore extends to a system for determining psychological stress in humans comprising first means for effecting use or a method (respectively) according to the first, second or third aspect of the present invention and second means for determining a secondary marker of psychological stress in humans, e.g. as indicated in the preceding paragraph.

15

#### Detailed description of the invention

By hereby identifying biological markers of psychological stress never previously associated with this clinical condition, the invention provides clear advantage over the art.

20 The total reliance on an individuals commonly inaccurate perception of their long term exposure to psychological stress has been removed. In its place a means of independently diagnosing this condition through a diagnostic method which measures isoprostanes levels in human tissue or body fluids is provided.

25 F<sub>2</sub>-isoprostanes measurement techniques for samples taken from human tissue or body fluid have been disclosed in the prior art and are commercially available. Cayman Chemicals provide suitable 8-isoprostane Enzyme Immunoassay Kits (eg Cat# 516358). US 2002/0072083 A1 of Fitzgerald et al., also discloses a means which is suitable for

measuring F<sub>2</sub>-isoprostanes and therefore can be used for the purpose of the present invention.

GC-MS remains the only other currently available method for detecting/characterising isoprostane species. However, once identified and purified (or synthesised) a similar route to the one we followed could be employed. Namely; conjugation of the selected isoprostane species to a carrier molecule, immunisation of mice and subsequent generation of specific monoclonal antibodies.

This means may comprise a sample container for carrying a tissue or body fluid sample from said mammal, a solution for use in isoprostane extraction, a negative and positive control solution for those not afflicted and afflicted respectively by psychological stress and an antibody directed against the isoprostane marker for psychological stress.

#### Description of figures

Figure 1 : illustrates a standard curve for 8-iso PGF<sub>2α</sub> detection by monoclonal 6527Ab, thereby providing the relationship between the number of counts and the inhibition by increasing the concentration of free 8-iso PGF<sub>2α</sub>. The curve was used to measure the concentrations in urine samples.

Figure 2: illustrates the correlation between urinary isoprostanes and salivary cortisol levels in humans.

Figure 3a: illustrates the relationship between perceived psychological stress and urinary isoprostanes.

Figure 3b: illustrates the relationship between perceived psychological stress and urinary isoprostane metabolites.

Figure 4: illustrates the correlation between 8-F<sub>2</sub>-IsoP and nor-adrenaline with increasing psychological stress.

## References:

- 5 Liu, T., Stern, A. et al.; The Isoprostanes: Novel prostaglandin-like products of the free radical catalysed peroxidation of arachidonic acid; Journal of Biomedical Science; 1999, Vol. 6, no.4 pp 226-235.
- 10 Morrow, J. D., Frei, B., Longmire, A. W. et al.; Increase in circulating products of lipid peroxidation (F-2- Isoprostanes) in smokers – smoking as a cause of oxidative damage. New England Journal of Medicine; 1995, Vol. 332, no.18, p. 1198-1203.
- Morrow, J. D., Jackson Roberts, L.; The Isoprostanes: Unique bioactive products of lipid peroxidation. Pro. Lipid Res. Vol.36, No. 1, pp 1-21, 1997.
- 15 Pruessner, J. C., Hellhammer, D. H., Kirschbaum, C.; Low self-esteem, induced failure and the adrenocortical stress response; Personality and Individual Differences; 1999, Vol. 27, no.3, p. 477-489.
- 20 Seeman, T. E., McEwen, B. S., ROWE, J. W. et al.; Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging; Proceedings of the National Academy of Sciences of the United States of America; 2001, Vol. 98, no.8, p. 4770-4775.
- 25 Seeman, T. E., Singer, B. H., ROWE, J. W. et al.; Price of adaptation - Allostatic load and its health consequences - MacArthur studies of successful aging; Archives of Internal Medicine; 1997, Vol. 157, no.19, p. 2259-2268.
- Cohen, S., Kamarck, T., Mermelstein, R.; A Global Measure of Perceived Stress; Journal of Health and Social Behavior; 1983, Vol. 24, p. 386-396.
- 30 Sapolsky, R. M.; Glucocorticoids, Neuroendangerment and Neurotoxicity; In: Encyclopedia of Stress; Academic Press, 2000; p. 238-244 Vol 2.
- 35 Lupien, S. J., Gaudreau, S., Tchiteya, B. M. et al.; Stress-induced declarative memory impairment healthy elderly subjects: Relationship to cortisol reactivity; Journal of Clinical Endocrinology and Metabolism; 1997, Vol. 82, no.7, p. 2070-2075.

Morrow, J. D., Roberts, L. J.; The isoprostanes: Unique bioactive products of lipid peroxidation; Progress in Lipid Research; 1997, Vol. 36, no.1, p. 1-21.

Vallieres, L., Rivest, S.; Interleukin-6 in the Central Nervous System; M-S Medecine Sciences; 2000, Vol 16, p.936-944.

### Example 1

#### Preparation of monoclonal antibody for isoprostane detection:

##### Immunogens

8-isoPGF<sub>2α</sub> purchased from Cayman Laboratories was conjugated using a number of carrier proteins (Keyhole Limpet Hemocyanin {KLH}, Bovine Serum Albumin {BSA} and Ovalbumin). The chemistry used was either carbodiimide (EDC) or mixed anhydride.

##### Immunisations

Female Balb/c mice were immunised subcutaneously and intra-peritoneally with 25-50 µg of appropriate immuno-conjugates. Each conjugate was mixed with an adjuvant formulation comprising aluminium hydroxide gel, saponin (Quil A) and *E. coli* lipopolysaccharide or Freund's. Booster injections were given on day 14 and sera from these mice were tested on day 21 to ascertain the most immunogenic conjugates. The animals with strongest immune responses were then used for fusions.

##### Fusions

Spleens from best-selected mice were perfused with culture media and the resulting lymphocyte suspension (approx. 10<sup>7</sup> cells per spleen) was combined with SP2/ 0 myeloma cells in a 1:1 ratio. After centrifugation at 200x g for 5 minutes, the supernatant was discarded and the pellet loosened. To this mixed pellet was added 1 ml of 45% PEG 3000 (Fluka AG batch No. 251778). The cells were centrifuged gently for 3 minutes and after a total contact time of 8 minutes, the PEG was gradually diluted and removed by addition of culture medium containing selection components, Hypoxanthine and Azaserine (HAZ) and dispensed into 10 x 48 well plates. Hybridomas were visible at day

3 and a medium change was given on day 7. Supernatants from all fusion wells, (480 samples per fusion) were assayed for anti-8-iso PGF<sub>2α</sub> activity.

#### Direct Assay - Enzyme Immunoassay (EIA)

5

Mouse antiserum and hybridoma culture supernatants were both tested by direct EIA. Greiner Microlon microtitre plates were sensitised overnight at 37°C with 8-iso-Ovalbumin conjugate at 1 µg /ml in bicarbonate coating buffer pH 9.8. Plates were then washed with phosphate buffered saline containing 0.05% Tween 20 (PBST). 100 µl volumes of each sample were then added and the plates incubated for 1 hour at 37°C. After further washing 100 µl volumes of indicator conjugate was added (rabbit anti-mouse, alkaline phosphatase labelled {Sigma Chemicals}), followed by washing and addition of PNPP substrate. Absorbance at 405 nm was measured after approximately 20 min. incubation.

#### 15 Inhibition Assay

Positive supernatants identified in direct EIA were then tested in an inhibition assay with free 8-iso PGF<sub>2α</sub> to confirm specificity. In this assay, supernatants were first titrated to determine the dilution, which gave 70% of their maximum absorbance. These dilutions were then pre-incubated for 30 minutes with 12 doubling dilutions of inhibitor (8-iso PGF<sub>2α</sub>) from an initial concentration of 10 µg/ ml. Subsequent steps are as described in Direct assay. Related prostaglandins were then included in the inhibition assay format and the full table of cross-reactivity can be seen in Table 1.



Table 1.

Cross-reactant	634 1	6363	6376	6482	6485	647 8	6486	6506	6480. 1	6496. 1	6497. 1	6527
1	100	100	100	100	100	100	100	100	100	100	100	100
2	3.13	0.3	5.1	0.07	0.06	1.09	0.11	0.61	1.81	0.38	0.38	0.1
3	-	-	-	-	-	-	-	-	-	-	-	-
4	2.16	0.26	1.73	0.23	1.14	2.39	1.12	0.45	2.47	1.66	1.66	0.21
5	2.78	0.59	2.91	0.12	0.35	1.98	0.53	3.96	2.67	1.71	0.45	3.16
6	0.83	0.11	0.08	0.83	5.29	0.63	7.11	0.15	0.52	0.3	7.21	0.13
7	0.13	0.02	0.05	0.05	0.01	0.04	0.01	-	-	-	-	0.12
8	1.02	0.11	0.51	0.37	1.51	2.23	2.33	0.09	3.59	2.01	2.63	0.62
9	0.85	0.18	0.07	0.07	0.02	0.14	0.01	-	-	-	-	0.14
10	0.06	0.03	0.03	0.03	0.01	0.01	0.01	-	-	-	-	0.09
11	0.08	0.04	0.06	0.05	2.46	1.21	3.09	0.03	0.49	0.08	3.47	0.13
12	0.08	0.06	0.03	0.26	2.87	0.24	3.21	0.04	0.18	0.14	4.03	0.13
13	0.21	0.04	0.08	0.02	0.02	0.02	0.01	-	-	-	-	0.13
Approx. sensng ml	4	8	0.6	4	0.8	1.6	0.4	0.4	0.4	0.3	0.35	0.05

1. 8-iso PGF<sub>2α</sub>2. Thromboxane B<sub>2</sub>

5 3. Arachidonic acid

4. Prostaglandin F<sub>2α</sub>5. 2,3-dinor-8-isoPGF<sub>1α</sub>6. 8-isoPGE<sub>2α</sub>7. 13,14-dihydro-15-ketoPGF<sub>2α</sub>10 8. PGD<sub>2</sub>

9. 11-dihydroThromboxaneB

10. 13,14-dihydro-15 ketoPGF<sub>2α</sub>11. 6-ketoPGF<sub>1α</sub>12. PGE<sub>2</sub>13. 6,15-Keto 13,14dihydroPGF<sub>1α</sub>

Table 1 shows the cross-reactivity patterns of the 12 selected antibodies. All of the antibodies give 100% cross-reactivity with 8-iso PGF<sub>2α</sub> itself. The other figures are the percentage of reactivity with the related compounds. The final row is the sensitivity of

each antibody to 8-iso PGF<sub>2α</sub>. ie. the concentration at which 50% inhibition is achieved. A lower figure represents a greater sensitivity.

#### Purified selected antibody production

5

Clones of interest were recloned to ensure monoclonality, expanded for cryogenic preservation and used for production of purified antibody. This was achieved by growth of cells in either roller bottles or stirred fermenters up to a volume of 8 litres. Once maximum volume and optimum cell density was attained cultures were converted to serum free production. Subsequently the supernatant containing monoclonal antibody was filtered, concentrated and passed down a Protein A Sepharose column to achieve purity.

#### Assay Development

15 A time-resolved fluorescence immunoassay for 8-iso PGF<sub>2α</sub> in urine was developed. The analysis of urine 8-iso PGF<sub>2α</sub> involves competition between free 8-iso PGF<sub>2α</sub> as standard or in urine and 8-iso PGF<sub>2α</sub> conjugated to europium (Eu<sup>3+</sup>) for the immobilised antibody on the microtitre plate. The standard curve for the assay is shown in Figure 1.

#### 20 Standard DELFIA™ format

50μl standard or sample were added to microplates coated with rabbit anti-mouse reagent (Perkin Elmer).

25 Antibody was diluted in DELFIA (Dissociation Enhanced Lanthanides Fluorometry Immunoassay Perkin Elmer) assay buffer and 100μl volumes added to the microplate. 50μl of EU<sup>3+</sup> labelled 8-iso PGF<sub>2α</sub> was then added at a predetermined concentration and the plate incubated shaken for 1 hour.

30 The assay was washed, incubated with enhancement solution and read in the Victor fluorometer. This assay determined the level of antibody and label to be used.

Subsequently, the predetermined levels of antibody and label were supplemented with known concentrations of free 8-iso PGF<sub>2α</sub> as inhibitor to set up a standard curve. Clinical urine samples could then be included in the assay as unknowns and were read off the standard curve.

35

A similar procedure was followed to establish a monoclonal antibody to 2,3-dinor-8-isoPGF<sub>1α</sub> and a DELFIA immunoassay was developed as described above, except with the use of a 2,3-dinor labelled tracer in place of the 8-iso PGF<sub>2α</sub>.

5

## Example 2

### Relationship between perceived stress, salivary cortisol response and urinary isoprostanes

10

A total of 40 participants (all female) were recruited with an average age of  $33.3 \pm 5.0$  years (mean  $\pm$  SD). 2 participants were excluded, on arrival for the study session, due to high resting heart rates ( $>90$  beats/min).

15

The study consisted of two phases, firstly the filling in of a questionnaire, described below. Secondly, individuals were asked to participate in a "stress-induction" procedure designed to measure stress in a defined way in the laboratory. This allows the quantification of a biological response (cortisol secretion) to the same stressful event in all subjects.

20

### Stress questionnaire

25

The perceived stress scale (PSS-10) is a 10 item questionnaire that has been developed by Cohen (Cohen S, Karmarck T and Mermelstein R; Global measures of perceived stress; Journal of Health and Social Behaviour; 1983, vol 24 p386-396), and is well validated. The questionnaire assesses the extent to which individuals feel that they are in control of the events in their lives. This concentration on the "locus of control" element has high face and construct validity since individuals suffering from depression report a very low sense of control over events in their lives. The sample median PSS score was calculated and subjects were characterised as high or low stress, contingent upon their position relative to that median.

30

### Stress Induction Procedure

35

The procedure used was the Trier Mental Challenge Test (TMCT). This is a stressful mental arithmetic test under time pressure with negative feedback given (Kirschbaum C,

Pirke KM and Hellhammer DH; The TRIER social stress test – a tool for investigating psychobiological stress responses in a laboratory setting; Neurophysiology; 1993, vol 28, no.1-2, p76-81; ISSN 0302-282). It is administered using a computer program developed by Pruessner et al. (1999). It was run on a single PowerMacintosh G3 (Power PC).

5 Participants were informed that they were performing a reaction time task to mental arithmetic sums and started with a 3 minute 'practice' session. This allowed the program to work out an average response time to sums. In the 'real' sessions (there were 3 sets of sums each lasting 4 mins) the program gave them less time than they required to complete the sums. The time limit for each sum was measured on screen by a black bar  
10 that moved across the screen and was coupled to a noise that increased in pitch as the time ran out. Participants recorded their answers by using the mouse to click on the on screen number pad. The computer would either show the word 'correct', 'incorrect' or 'timeout' (with the latter 2 being accompanied by a louder beep) depending on how the participant had answered the sum. At the top of the screen a bar with an arrow above and  
15 below which indicated to the participant how well they were performing in relation to a population average. They were told that they must achieve this average score in order that their reaction time data could be used.

The experimenter was present to give feedback between sets of sums to reinforce the  
20 fact that they were performing badly. It is known in the literature that the combination of internalised failure and negative feed-back during the test period induces a temporary loss of self-esteem and therefore a greater "stress response".

### Control Setting

25 The participants in the control setting carried out a similar task to the 'stress' group using the same TMCT program. In this case the 'control setting' was used in the program which meant there was no time limit (no black bar or noise), they had very easy sums and were not compared to other people. The experimenter gave positive feedback to the  
30 participants between sets of sums. Both the stress induction procedure and the control condition lasted 15-20mins.

### Cortisol sampling

35 Prior to the test beginning, saliva samples were taken twice at ten minute intervals for analysis of cortisol levels. The average of these two samples served as a "baseline" sample for comparison between "rest" and "stress" levels. A saliva sample was taken

immediately after the test and then every ten minutes post stressor for 30 minutes. This allowed for the measurement of stress for a period of time "post stress".

Cortisol levels were measured in saliva since it is a non-invasive method and avoided any stress response as a result of having blood taken. It is a reliable way to measure free, unbound cortisol (representing the biologically active portion of cortisol) and correlates to total cortisol levels in plasma. The saliva samples were taken using "Salivettes" (supplied by Starstedt). This required participants to chew lightly on the salivette (cotton roll) for one minute or until the salivette was soaked. This is the recommended way to collect saliva for the cortisol assay used.

Measurement of salivary cortisol was performed using a high sensitivity salivary cortisol enzyme immunoassay kit from Salimetrics.

Saliva was collected using plain cotton Salivettes (Sarstedt). Samples were frozen to precipitate mucins, thawed completely, vortexed and centrifuged at 1500g for 15 minutes. 25µl standard or prepared saliva sample were added in replicate to a microtitre plate coated with rabbit antibodies to cortisol. An addition of conjugate – cortisol linked to the enzyme horseradish peroxidase, is made and cortisol in the standards or samples compete with conjugate for the antibody binding sites on the plate. After an hours incubation the plate is washed to remove unbound conjugate and substrate added. The amount of bound enzyme-cortisol conjugate in the well is inversely proportional to the concentration of cortisol in the sample. The intensity of colour developed is read at 450nm (reference 620nm) and the measured ODs of the standards are used to construct a calibration curve against which the unknown samples are calculated.

Plates were read on a Victor 2 1420 Multilabel counter (Perkin Elmer). A Multicalc data reduction package determines individual sample concentrations from the appropriate standard curve for each assay plate.

Results shown in figure 2.

#### Urinary Isoprostanes

Participants collected their first "early morning" urine sample in collection pots provided and then transferred this to a universal tube. The tube contained azid preservative and

was stored, on receipt, at  $-20^{\circ}\text{C}$ . An early morning sample was used in order to minimise the potential influence of diet and physical activity on basal isoprostane levels and measurements were made in accordance with example 1.

## 5 Statistical analysis

### Perceived Stress and Isoprostanes:

Perceived Stress scores were split by the sample median, therefore defining 50% of the sample as low stress and the other half as high stress. The sample median was similar to that reported in the validation paper for other populations (Cohen et al. 1985). Examination of the data indicated non-normality in the data-set. Therefore non-parametric tests were deemed appropriate and subsequently a Mann-Whitney U test was carried out to test for differences between the high and low stress groups in isoprostane levels. This revealed a significant difference between the two groups ( $U=110$ ,  $p<0.05$ ), with the high stress group producing increased levels of urinary isoprostanes. A significant difference was also observed in production of isoprostane metabolites between the high and low stress groups ( $U=106$ ,  $p<0.05$ ). The mean values of the transformed and untransformed data can be seen in Table 2.

Table 2: Levels of urinary isoprostanes and their metabolites for high and low perceived stress groups. Data shown are means (+/- s.e.m). \* $p<0.05$

	Urinary isoprostanes (mean,ng/ml +/- s.e.m)	Urinary isoprostane metabolites(mean,ng/ml +/- s.e.m)
High Stress	9.10(+/-1.28)	34.93(+/-5.96)
Low Stress	5.78(+/-1.21)	23.11(+/-4.56)

### Stress-induced cortisol and isoprostane levels:

In order to check that the stress induction worked, and that cortisol secretion increased as a result of the stress induction, a repeated measures analysis of variance (MANOVA) was computed with time and stress conditions as a within and between-subjects factor respectively, and with greenhouse-geiser corrections used. This demonstrated a

significant time by condition interaction, such that the amount of cortisol secreted over time was greater in the stress condition than the control condition ( $F_{3,33} = 5.56$ ,  $p = 0.01$ ).

Furthermore, in the group subjected to a stressor, there were no positive correlations between the levels of cortisol at baseline (rest) and cortisol levels after the stressor (range of correlations ( $r$ 's) =  $-.13$  to  $0.4$ ), indicating that baseline cortisol changed over the course of the stressor for this group. In the control group, baseline cortisol levels did positively correlate with the cortisol levels measured at each interval during the stressor (range of  $r$ 's =  $0.6$  to  $0.82$ ) indicating that these levels were stable over the time period assessed.

These results together show that cortisol secretion was altered in the stress group alone, over the course of the stress period. This reflects the increased activity of the HPA axis, indicative of increased acute stress.

Having established that the stress group was indeed demonstrating physiological signs of "stress", we assessed the relationship between these biomarkers and the isoprostane levels. In particular the relationship with respect to the early morning urine levels. In order to investigate the relationship between isoprostanes and the extent of stress reactivity (indexed by cortisol levels during the stressor), urinary isoprostanes were correlated with the salivary cortisol levels over the timecourse of sampling. These can be seen in the table below:-

Table 3: Correlations between urinary isoprostanes and cortisol secreted during stress period for both "stress" and "control" groups. Data shown are  $r$ -values ( $**p < 0.01$ ).

	Cortisol at baseline	Cortisol at 10 mins post stress	Cortisol at 20 mins post stress	Cortisol at 30 mins post stress
Isoprostanes in Stress group	.36	.78**	.76**	.61**
Isoprostanes in Control group	.21	-.04	-.05	-.05

These results demonstrate that the levels of urinary isoprostanes predict the extent to which individuals secrete more cortisol during a stressful period. There was no correlation observed between cortisol levels observed within the control group over the same period.

- 5 This suggests that the influence of prior lipid peroxidation state on cortisol responsiveness is restricted to instances of physiological/psychological stress.

- 10 In total, the demonstration that reported perceived stress correlates with the isoprostane levels, and their metabolites, found in urine, and the observation that stress reactivity, as indexed by cortisol secretion occurring during a stress period, is related to the base level of isoprostanes produced indicates that isoprostanes and stress are related. It is therefore proposed that isoprostanes, as an exemplar of a biomarker of lipid peroxidation, is also a marker of the psychologically stressed state of an individual. It is further proposed that the metabolites of the isoprostanes are also related to states of  
15 psychological stress.

### Example 3

#### Relationship between urinary noradrenaline and urinary isoprostanes.

20

- In this study, 39 women in the age range 50-65 years were recruited. Participants were asked to collect their first urine sample of the morning in collection pots then transfer it to universal tube. The tubes were kept at 4°C for less than 24 hours and then kept at -24°C. The levels of isoprostanes in the urine were measured as previously described. The  
25 measurement of noradrenaline levels in the urine were as described below.

- Measurement of Noradrenaline was carried out using a CatCombi ELISA kit ([www.IBL-HAMBURG.COM](http://www.IBL-HAMBURG.COM)) distributed by RDI. These kit(s) are sandwich enzyme immunoassays which provide quantitative determination of the catecholamine, noradrenaline, in 10µl  
30 human urine.

- Urine samples firstly undergo an extraction process, followed by an incubation with more extraction buffer and an acylation reagent in microtiter plates coated with boronate-affinity gel. Following a washing step Release buffer is placed into all wells, and the  
35 plates are stored overnight at 4°C. The extracted samples are then placed into an appropriate microtitre plate. To test for Noradrenaline, a plate coated with an antibody



against N-acyl-normetanephrene is used. The plates are washed, and a second antibody directed towards a different region of the antigen molecule, conjugated to alkaline phosphatase is added. After incubation the unbound second antibody is washed off, and substrate added. The amount of bound enzyme-conjugated antibody in the well is proportional to the concentration of antigen in the sample. The intensity of colour developed is read at 490nm (reference 620nm) and the measured ODs of the standards are used to construct a calibration curve against which the unknown samples are calculated.

- 10 The enzyme immunoassays were read on a Victor 2 1420 Multilabel counter (Perkin Elmer). A Multicalc data reduction package determined individual sample concentrations from the appropriate standard curve for each assay plate.

Urinary isoprostanes were measured in accordance with the previous examples.

- 15 Correlational data were calculated between the levels of noradrenaline and isoprostanes measured in the overnight urine sample. These analyses revealed that noradrenaline and isoprostone levels were positively correlated, and that the correlations reached statistical significance ( $r=0.61, p<0.01$ ). Scatterplots of the data are shown in figure 4.

20

25

**CLAIMS**

- 5     1. Use of one or more isoprostanes as a biological marker of psychological stress in humans.
2. Use of a means for measuring one or more isoprostanes in determining psychological stress levels in humans.
- 10    3. Use according to claim 2, wherein said means for measuring said one or more isoprostanes comprises one or more antibodies and/or antibody fragments directed thereto.
- 15    4. Use according to any one of claims 1 to 3, wherein said one or more isoprostanes are measured in one or more fluids selected from urine, blood, tears, sweat and saliva.
- 20    5. Use according to claim 4, wherein said psychological stress is associated with one or more conditions selected from the group comprising clinical depression, post traumatic stress disorder, chronic fatigue syndrome and ME.
- 25    6. Use according to claim 4, wherein said one or more isoprostanes when measured in urine comprises 2,3-dinor-8-iso-prostaglandin  $F_{1\alpha}$  and/or a racemic diastereoisomer thereof.
7. Use according to any one of the preceding claims wherein said one or more isoprostane is an F2-isoprostane.
- 30    8. Use according to any one of the preceding claims, wherein said one or more isoprostane is a 8-F<sub>2</sub>-IsoP and/or a racemic diastereoisomer thereof.

**Abstract**

5

**Psychological Stress In Humans**

10

The present invention relates to the field of psychological stress in humans, more particularly the invention relates to the diagnosis of human psychological stress through the use of isoprostanes as a biological marker.



Figure 1






Figure 2









Figure 3A



\* p&lt;0.05




Figure 3B







Figure 4



$R=0.61, (p<0.01)$

